Publications by authors named "R B Colletti"
Article Synopsis
- A multicenter trial was conducted to compare the effectiveness of tumor necrosis factor inhibitors combined with oral methotrexate versus those without methotrexate in pediatric patients with Crohn's disease.
- The study involved 297 participants, revealing that combination therapy did not significantly improve treatment outcomes for infliximab initiators, but did show a longer time to treatment failure for adalimumab initiators.
- Although combination therapy led to more adverse events overall, it resulted in fewer serious adverse events, with no significant differences reported in patient-reported outcomes of pain and fatigue.
Article Synopsis
- Biologic medications are recommended for treating moderate to severe Crohn disease and ulcerative colitis in children, but many may need additional treatments due to lack of response or losing effectiveness.
- A study of pediatric inflammatory bowel disease showed that 43% of patients received biologics before age 18, with a higher likelihood for Crohn disease compared to ulcerative colitis, and anti-tumor necrosis factor agents were the most common first biologics used.
- Discontinuation of the first biologic was often due to loss of response, intolerance, or nonresponse, and several factors can predict how long these medications will be effective in young patients with IBD.
To evaluate the performance of the multiple imputation (MI) method for estimating clinical effectiveness in pediatric Crohn's disease in the ImproveCareNow registry; to address the analytical challenge of missing data. Simulation studies were performed by creating missing datasets based on fully observed data from patients with moderate-to-severe Crohn's disease treated with non-ustekinumab biologics. MI was used to impute sPCDAI remission statuses in each simulated dataset.
View Article and Find Full Text PDFBackground: To assess disease activity, steroid-free remission, and other clinical outcome assessments among pediatric patients with ulcerative colitis (UC) and Crohn's disease (CD) in the ImproveCareNow (ICN) registry.
Methods: Patients aged 2-17 years diagnosed with UC or CD between June 1, 2013 and December 31, 2019 were enrolled if they initiated a biologic after enrollment in the ICN registry and completed at least 12 months follow-up after first maintenance dose. Baseline (at biologic initiation) demographics were summarized using descriptive statistics.